Yesim Gökmen‐Polar

Author

Yesim Gökmen‐Polar

Indiana University – Purdue University Indianapolis ORCID

Also Known As

Gökmen-Polar, Yesim, Loehrer, P.J., Y GOKMENPOLAR, Y Gokmen-Polar, Y Gökmen-Polar, Y Gökmen-Polar, Y. Gokmen-Polar, YESIM GÖKMEN, Yesim Gokmen-Polar, Yesim Gökmen-Polar

179

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis Indiana University School of Medicine Indiana University Health National Cancer Institute Emory University

About

Yesim Gökmen‐Polar is an author at Indiana University – Purdue University Indianapolis specializing in medicine, pathology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	867
2	Cell Biology	9	9	563
3	Engineering	1	1	27
4	Public Health	1	1	13
5	Biostatistics	1	1	27

Yesim Gökmen‐Polar

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
The Integrated Genomic Landscape of Thymic Epithelial Tumors Milan Radovich, Curtis R. Pickering, Ina Felau, Cancer Cell	2018	366
Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Yesim Gökmen‐Polar, Nicole R. Murray, Marco A. De Velasco, PubMed Chemoprevention StrategyPathologyCancer BiologyTumor BiologySignaling Pathway	2001	182
Protein kinase Cι is required for Ras transformation and colon carcinogenesis in vivo Nicole R. Murray, Lee Jamieson, Wangsheng Yu, The Journal of Cell Biology	2004	139
CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer Kelly E. Craven, Yesim Gökmen‐Polar, Sunil Badve Scientific Reports	2021	134
Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients Renata Duchnowska, Jacek Jassem, Chirayu Goswami, Journal of Neuro-Oncology Neuro-oncologyEarly Brain MetastasesBreast OncologyVisceral LocationMedicine	2015	88
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models Yesim Gökmen‐Polar, Yi Liu, Rachel A. Toroni, Breast Cancer Research and Treatment Tumor BiologyMedicinePharmacologyInvestigational Drug Mln0128Novel Torc1/2 Inhibitor	2012	79
Splicing factor <i> <scp>ESRP</scp> 1 </i> controls <scp>ER</scp> ‐positive breast cancer by altering metabolic pathways Yesim Gökmen‐Polar, Yaseswini Neelamraju, Chirayu Goswami, EMBO Reports Transcriptional RegulationMetabolic PathwaysMedicineCancer Cell BiologyPathology	2019	79
EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Ming Lü, Kathy D. Miller, Yesim Gökmen‐Polar, PubMed Tamoxifen SensitivityBreast OncologyEstrogen DependenceMedicineHormonal Receptor	2003	70
DNA Double-Strand Break Repair Genes and Oxidative Damage in Brain Metastasis of Breast Cancer Stephan Woditschka, Lynda M. Evans, Renata Duchnowska, JNCI Journal of the National Cancer Institute	2014	67
Prognostic Impact of HOTAIR Expression is Restricted to ER-Negative Breast Cancers Yesim Gökmen‐Polar, Ioan Tudor Vladislav, Yaseswini Neelamraju, Scientific Reports	2015	65

Page 1